BcL-xL Conformational Changes upon Fragment Binding Revealed by NMR

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Aguirre, Clémentine ^a   ten Brink, Tim ^a   Walker, Olivier ^a   Guillière, Florence ^a   Davesne, Dany ^a   Krimm, Isabelle ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL XL;

ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; LIGAND BINDING; NONHUMAN; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE;

BCL-X PROTEIN; BENZOATES; BINDING SITES; BIPHENYL COMPOUNDS; DRUG DISCOVERY; HUMANS; MOLECULAR DOCKING SIMULATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; STRUCTURAL HOMOLOGY, PROTEIN; SURFACE PROPERTIES; THERMODYNAMICS;

EID: 84878164756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064400     Document Type: Article

References (76)

1. Braun P, Gingras AC, (2012) History of protein-protein interactions: from egg-white to complex networks. Proteomics 12: 1478-1498.
2. Surade S, Blundell TL, (2012) Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem Biol 19: 42-50.
3. Scott DE, Ehebauer MT, Pukala T, Marsh M, Blundell TL, et al. (2013) Using a fragment-based approach to target protein-protein interactions. Chembiochem 14: 332-342.
4. Morelli X, Bourgeas R, Roche P, (2011) Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2p2i). Curr Opin Chem Biol 15: 475-481.
5. Sperandio O, Reyns CH, Camproux AC, Villoutreix BO, (2010) Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today 15: 220-229.
6. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, et al. (2003) Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci U S A 100: 1603-1608.
7. Bower JF, Pannifer A, (2012) Using fragment-based technologies to target protein-protein interac-tions. Curr Pharm Des 18: 4685-4696.
8. Molle IV, Thomann A, Buckley DL, So EC, Lang S, et al. (2012) Dissecting fragment-based lead discovery at the von hippel-lindau protein:hypoxia inducible factor 1alpha protein-protein interface. Chem Biol 19: 1300-1312.
9. Kuo LC (2011) Fragment-based drug design: tools, practical approaches, and exemples. San Diego: Academic Press. 591 p.
10. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW, (1996) Discovering high-affinity ligands for proteins: Sar by nmr. Science 274: 1531-1534.
11. Hopkins AL, Groom CR, Alex A, (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9: 430-431.
12. Bembenek SD, Tounge BA, Reynolds CH, (2009) Ligand efficiency and fragment-based drug dis-covery. Drug Discov Today 14: 278-283.
13. Carr RAE, Congreve M, Murray CW, Rees DC, (2005) Fragment-based lead discovery: leads by design. Drug Discov Today 10: 987-992.
14. Petros AM, Huth JR, Oost T, Park CM, Ding H, et al. (2010) Discovery of a potent and selective bcl-2 inhibitor using sar by nmr. Bioorg Med Chem Lett 20: 6587-6591.
15. Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, et al. (2006) Discovery of a potent inhibitor of the antiapoptotic protein bcl-xl from nmr and parallel synthesis. J Med Chem 49: 656-663.
16. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, et al. (2007) Crystal structure of abt-737 complexed with bcl-xl: implications for selectivity of antagonists of the bcl-2 family. Cell Death Differ 14: 1711-1713.
17. Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, et al. (2013) Discovery of potent myeloid cell leukemia 1 (mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem 56: 15-30.
18. Rega MF, Wu B, Wei J, Zhang Z, Cellitti JF, et al. (2011) Sar by interligand nuclear overhauser effects (iloes) based discovery of acylsulfonamide compounds active against bcl-x(l) and mcl-1. J Med Chem 54: 6000-6013.
19. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, et al. (2003) Discovery of a potent small molecule il-2 inhibitor through fragment assembly. J Am Chem Soc 125: 3714-3715.
20. Tsao DHH, Sutherland AG, Jennings LD, Li Y, Rush TS, et al. (2006) Discovery of novel inhibitors of the zipa/ftsz complex by nmr fragment screening coupled with structure-based design. Bioorg Med Chem 14: 7953-7961.
21. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, et al. (2012) Discovery of small molecules that bind to k-ras and inhibit sos-mediated activation. Angew Chem Int Ed Engl 51: 6140-6143.
22. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, et al. (2012) Small-molecule ligands bind to a distinct pocket in ras and inhibit sos-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 109: 5299-5304.
23. Murray CW, Verdonk ML, Rees DC, (2012) Experiences in fragment-based drug discovery. Trends Pharmacol Sci 33: 224-232.
24. Perryman AL, Zhang Q, Soutter HH, Rosenfeld R, McRee DE, et al. (2010) Fragment-based screen against hiv protease. Chem Biol Drug Des 75: 257-268.
25. Babaoglu K, Shoichet BK, (2006) Deconstructing fragment-based inhibitor discovery. Nat Chem Biol 2: 720-723.
26. Carra JH, McHugh CA, Mulligan S, Machiesky LM, Soares AS, et al. (2007) Fragment-based identification of determinants of conformational and spectroscopic change at the ricin active site. BMC Struct Biol 7: 72.
27. Haigh C, Mallion R, (1979) Ring current theories in nuclear magnetic resonance. Prog Nucl Magn Reson Spectrosc 13: 303-344.
28. Neal S, Nip AM, Zhang H, Wishart DS, (2003) Rapid and accurate calculation of protein 1 h, 13c and 15n chemical shifts. J Biomol NMR 26: 215-240.
29. Xu XP, Case DA, (2001) Automated prediction of 15n, 13calpha, 13cbeta and 13c′ chemical shifts in proteins using a density functional database. J Biomol NMR 21: 321-333.
30. McCoy MA, Wyss DF, (2000) Alignment of weakly interacting molecules to protein surfaces using simulations of chemical shift perturbations. J Biomol NMR 18: 189-198.
31. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
32. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, et al. (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival b-cell lymphoma 2 proteins. J Med Chem 51: 6902-6915.
33. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, et al. (2013) Targeting the bcl-2 family for cancer therapy. Expert Opin Ther Targets 17: 61-75.
34. van Delft MF, Huang DCS, (2006) How the bcl-2 family of proteins interact to regulate apoptosis. Cell Res 16: 203-213.
35. Youle RJ, Strasser A, (2008) The bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
36. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, et al. (1997) Structure of bcl-xl-bak peptide complex: recognition between regulators of apoptosis. Science 275: 983-986.
37. Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, et al. (2000) Rationale for bcl-xl/bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9: 2528-2534.
38. Liu X, Dai S, Zhu Y, Marrack P, Kappler JW, (2003) The structure of a bcl-xl/bim fragment complex: implications for bim function. Immunity 19: 341-352.
39. Feng W, Huang S, Wu H, Zhang M, (2007) Molecular basis of bcl-xl's target recognition versatility revealed by the structure of bcl-xl in complex with the bh3 domain of beclin-1. J Mol Biol 372: 223-235.
40. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, et al. (2007) Studies leading to potent, dual inhibitors of bcl-2 and bcl-xl. J Med Chem 50: 641-662.
41. Constantine KL, Davis ME, Metzler WJ, Mueller L, Claus BL, (2006) Protein-ligand noe matching: a high-throughput method for binding pose evaluation that does not require protein nmr resonance assignments. J Am Chem Soc 128: 7252-7263.
42. Metzler WJ, Caus BL, McDonnell PA, Johnson SR, Goldfarb V, et al. (2008) Application of protein-ligand NOE matching to the rapid evaluation of fragment binding poses. In: Zartler ER, Shapiro MJ, editors. Fragment-Based Drug Discovery. Chichester: John Wiley and sons. pp. 99-133.
43. Tolman JR, (2001) Dipolar couplings as a probe of molecular dynamics and structure in solution. Curr Opin Struct Biol 11: 532-539.
44. Hu W, Wang L (2006) Residual dipolar couplings: Measurements and applications to biomolecular studies. In: Webb GA, editor, Annual Reports on NMR Spectroscopy, Academic Press, volume 58 of Annual Reports on NMR Spectroscopy. pp. 231-303.
45. Hagn F, Klein C, Demmer O, Marchenko N, Vaseva A, et al. (2010) Bclxl changes conformation upon binding to wild-type but not mutant p53 dna binding domain. J Biol Chem 285: 3439-3450.
46. Zhang D, Raasi S, Fushman D, (2008) Affinity makes the difference: nonselective interaction of the uba domain of ubiquilin-1 with monomeric ubiquitin and polyubiquitin chains. J Mol Biol 377: 162-180.
47. Umemoto K, Leffler H, Venot A, Valafar H, Prestegard JH, (2003) Conformational differences in liganded and unliganded states of galectin-3. Biochemistry 42: 3688-3695.
48. Tian F, Al-Hashimi HM, Craighead JL, Prestegard JH, (2001) Conformational analysis of a exible oligosaccharide using residual dipolar couplings. J Am Chem Soc 123: 485-492.
49. Barelier S, Pons J, Marcillat O, Lancelin JM, Krimm I, (2010) Fragment-based deconstruction of bcl-xl inhibitors. J Med Chem 53: 2577-2588.
50. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) Autodock4 and autodock-tools4: Automated docking with selective receptor exibility. J Comput Chem 30: 2785-2791.
51. Wang YS, Strickland C, Voigt JH, Kennedy ME, Beyer BM, et al. (2010) Application of fragment-based nmr screening, x-ray crystallography, structure-based design, and focused chemical library design to identify novel microm leads for the development of nm bace-1 (beta-site app cleaving enzyme 1) inhibitors. J Med Chem 53: 942-950.
52. Novak W, Wang H, Krilov G, (2009) Role of protein exibility in the design of bcl-x(l) targeting agents: insight from molecular dynamics. J Comput Aided Mol Des 23: 49-61.
53. Yang CY, Wang S, (2012) Analysis of exibility and hotspots in bcl-xl and mcl-1 proteins for the design of selective small-molecule inhibitors. ACS Medicinal Chemistry Letters 3: 308-312.
54. McCoy MA, Wyss DF, (2002) Spatial localization of ligand binding sites from electron current density surfaces calculated from nmr chemical shift perturbations. J Am Chem Soc 124: 11758-11763.
55. Gonzlez-Ruiz D, Gohlke H, (2009) Steering protein-ligand docking with quantitative nmr chemical shift perturbations. J Chem Inf Model 49: 2260-2271.
56. Wishart DS, Case DA, (2001) Use of chemical shifts in macromolecular structure determination. Methods Enzymol 338: 3-34.
57. Parker LL, Houk AR, Jensen JH, (2006) Cooperative hydrogen bonding effects are key determinants of backbone amide proton chemical shifts in proteins. J Am Chem Soc 128: 9863-9872.
58. Moon S, Case DA, (2007) A new model for chemical shifts of amide hydrogens in proteins. J Biomol NMR 38: 139-150.
59. Wyss DF, Arasappan A, Senior MM, Wang YS, Beyer BM, et al. (2004) Non-peptidic small-molecule inhibitors of the single-chain hepatitis c virus ns3 protease/ns4a cofactor complex discov-ered by structure-based nmr screening. J Med Chem 47: 2486-2498.
60. Cioffi M, Hunter CA, Packer MJ, Spitaleri A, (2008) Determination of protein-ligand binding modes using complexation-induced changes in (1)h nmr chemical shift. J Med Chem 51: 2512-2517.
61. Cioffi M, Hunter CA, Packer MJ, Pandya MJ, Williamson MP, (2009) Use of quantitative (1)h nmr chemical shift changes for ligand docking into barnase. J Biomol NMR 43: 11-19.
62. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, et al. (1995) Nmrpipe: a multidimensional spectral processing system based on unix pipes. J Biomol NMR 6: 277-293.
63. Johnson BA, Blevins RA, (1994) Nmr view: A computer program for the visualization and analysis of nmr data. J Biomol NMR 4: 603-614.
64. Goddard TD, Kneller DG (2004) Sparky 3. University of California, San Fransisco, CA.
65. Schumann FH, Riepl H, Maurer T, Gronwald W, Neidig KP, et al. (2007) Combined chemical shift changes and amino acid specific chemical shift mapping of protein-protein interactions. J Biomol NMR 39: 275-289.
66. Hunter CA, Packer MJ, (1999) Complexation-induced changes in 1 h nmr chemical shift for supramolecular structure determination. Chem Eur J 5: 1891-1897.
67. Sahakyan AB, Vranken WF, Cavalli A, Vendruscolo M, (2011) Structure-based prediction of methyl chemical shifts in proteins. J Biomol NMR 50: 331-346.
68. Shen Y, Bax A, (2007) Protein backbone chemical shifts predicted from searching a database for torsion angle and sequence homology. J Biomol NMR 38: 289-302.
69. Christensen AS, Sauer SPA, Jensen JH, (2011) Definitive benchmark study of ring current effects on amide proton chemical shifts. J Chem Theory Comput 7: 2078-2084.
70. Ottiger M, Delaglio F, Bax A, (1998) Measurement of j and dipolar couplings from simplified two-dimensional nmr spectra. J Magn Reson 131: 373-378.
71. Varadan R, Walker O, Pickart C, Fushman D, (2002) Structural properties of polyubiquitin chains in solution. J Mol Biol 324: 637-647.
72. Losonczi JA, Andrec M, Fischer MW, Prestegard JH, (1999) Order matrix analysis of residual dipolar couplings using singular value decomposition. J Magn Reson 138: 334-342.
73. Clore GM, Garrett DS, (1999) R-factor, free r, and complete cross-validation for dipolar coupling refinement of nmr structures. J Am Chem Soc 121: 9008-9012.
74. Laskowski RA, Swindells MB, (2011) Ligplot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51: 2778-2786.
75. Manion MK, O'Neill JW, Giedt CD, Kim KM, Zhang KYZ, et al. (2004) Bcl-xl mutations suppress cellular sensitivity to antimycin a. J Biol Chem 279: 2159-2165.
76. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, et al. (1996) X-ray and nmr structure of human bcl-xl, an inhibitor of programmed cell death. Nature 381: 335-341.